| paricalcitol / Generic mfg. |
NCT01071070: Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease |
|
|
| Completed | 3b | 216 | RoW | paricalcitol, ABT-358, Zemplar | Abbott | Chronic Kidney Disease | 11/10 | 11/10 | | |
NCT00646035: A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis |
|
|
| Completed | 3 | 75 | US, Europe | paricalcitol capsules, ABT-358, Zemplar, paricalcitol | Abbott | End Stage Renal Disease | 11/02 | | | |
NCT00048451: Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) |
|
|
| Completed | 3 | 68 | US, Europe | paricalcitol | Abbott | Renal Insufficiency, Chronic | | | | |
NCT00048516: Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing) |
|
|
| Completed | 3 | 68 | US, Europe | paricalcitol capsule | Abbott | Renal Insufficiency, Chronic | | | | |
NCT00048438: Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) |
|
|
| Completed | 3 | 68 | US, Europe | paricalcitol | Abbott | Renal Insufficiency, Chronic | | | | |
| Terminated | 3 | 12 | US, Europe, RoW | paricalcitol injection 4 mcg/mL, ABT-358, paricalcitol, Zemplar, Placebo Injection 4 mcg/mL, placebo | Abbott, Massachusetts General Hospital, Harvard University | Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular | 05/09 | 05/09 | | |
NCT00599963: Paricalcitol for the Treatment of Immunoglobulin A Nephropathy |
|
|
| Withdrawn | 3 | 0 | RoW | paricalcitol | Chinese University of Hong Kong | IgA Nephropathy | 10/09 | 12/09 | | |
| Completed | 3 | 227 | US, Europe, RoW | paricalcitol, ABT-358, Zemplar, placebo | AbbVie (prior sponsor, Abbott), Massachusetts General Hospital | Chronic Kidney Disease, Left Ventricular Hypertrophy | 09/10 | 03/12 | | |
|
NCT00091975: Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis |
|
|
| Completed | 3 | 78 | US | Zemplar Capsule | Abbott | Kidney Disease | | | | |
VINCA-CKD, NCT01012414: Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease |
|
|
| Terminated | 3 | 10 | US | paricalcitol, Zemplar, placebo | Thomas Jefferson University, Abbott | Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism | 05/11 | 05/11 | | |
NCT01341782: Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism |
|
|
| Completed | 3 | 255 | Japan | paricalcitol, ABT-358, Zemplar, maxacalcitol, oxarol, paricalcitol placebo, maxacalcitol placebo | AbbVie (prior sponsor, Abbott) | Secondary Hyperparathyroidism, Hemodialysis | 04/12 | 04/12 | | |
|
NCT00417612: Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets |
|
|
| Completed | 3 | 33 | US | Paricalcitol, Zemplar, Placebo | Yale University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Hypophosphatemia, Familial, Hyperparathyroidism | 08/12 | 08/12 | | |
PENNY, NCT01680198: Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the Study) |
|
|
| Completed | 3 | 88 | Europe | Paracalcitol, Active form of Vitamin D., placebo | Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy | Chronic Kidney Disease. | 08/12 | 08/12 | | |
|
|
| Completed | 3 | 31 | Europe | Paricalcitol, Paricalcitol, atorvastatin, Atorvastatin | Effice Servicios Para la Investigacion S.L., FUNDACIÓN SENEFRO | Kidney Disease | 10/13 | 03/14 | | |
| Completed | 3 | 31 | Europe | Paricalcitol, Group 1, Paricalcitol, atorvastatin, G2, Atorvastatin, G3 | Ricardo Mouzo Mirco | Chronic Kidney Disease | 10/13 | 03/14 | | |
NCT01020487 / 2010-019439-37: Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD) |
|
|
| Completed | 3 | 47 | NA | Paricalcitol, Zemplar, Placebo | AbbVie (prior sponsor, Abbott) | Chronic Kidney Disease Stage 3 and 4 | 05/14 | 12/14 | | |
| Completed | 3 | 168 | Europe | Paricalcitol, Zemplar, Placebo | University Medical Centre Ljubljana, Abbott | Disorder of Transplanted Kidney, Proteinuria, Albuminuria | 10/14 | 07/15 | | |
NCT01694160: Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria |
|
|
| Completed | 3 | 77 | Europe | Paricalcitol | Oslo University Hospital | Proteinuria | 01/15 | 12/15 | | |
NCT01382212 / 2013-002610-13: A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis |
|
|
| Completed | 3 | 13 | NA | paricalcitol, ABT-358, Zemplar | AbbVie (prior sponsor, Abbott) | End-Stage Renal Disease, Secondary Hyperparathyroidism | 04/15 | 04/15 | | |
NCT02282813: Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 |
|
|
| Completed | 3 | 298 | US | CTAP101 Capsules, Calcifediol, Calcitriol, calcifediol, Doxercalciferol, Paricalcitol | OPKO Health, Inc. | Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency | 05/15 | 05/15 | | |
ExtenD, NCT01138475: Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery |
|
|
| Completed | 3 | 49 | US | Paricalcitol, Cholecalciferol, Placebo | Kerstyn C. Zalesin, M.D., Abbott | Gastric Bypass, Parathyroid Hormone | 08/15 | 08/15 | | |
2007-006606-16: The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification regulation (fetuin-A levels) in CKD stage 5D patients |
|
|
| Completed | 3 | 50 | Europe | Paricalcitol Capsules, Zemplar Weichkapsel, Zemplar Weichkapsel | University of Wuerzburg | Chronic kidney disease | | 03/11 | | |
2010-024023-25: ENSAYO CLÍNICO, ABIERTO, DE GRUPOS PARALELOS, FASE III, PARA VALORAR EL EFECTO ANTIPROTEINÚRICO DE LOS DERIVADOS DE LA VITAMINA D EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA E INSUFICIENCIA DE VITAMINA D. |
|
|
| Ongoing | 3 | 174 | Europe | zemplar, Hidroferol, 68022, Zemplar, Hidroferol, Zemplar, Hidroferol | Lorenzo Victor, PhD, Ministerio de Sanidad y Política Social (national health system) | Enfermedad renal crónica estadio II a IV más proteinuria residual >0,5 gr/día (en dos o más ocasiones consecutivas) más tratamiento con bloqueantes del SRAA durante al menos 3 meses. Niveles séricos de calcifediol en rango de insuficiencia (15-30 ng/ml). | | | | |
2009-016159-23: Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study |
|
|
| Ongoing | 3 | 30 | Europe | paricalcitol, ramipril, RVG 100436, RVG28004, paricalcitol, ramipril, paricalcitol, ramipril | University Medical Center Groningen (UMCG) | chronic kidney disease | | | | |
NCT04994080: A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism |
|
|
| Not yet recruiting | 3 | 84 | NA | Paricalcitol, Placebo | Chengdu Suncadia Medicine Co., Ltd. | Secondary Hyperparathyroidism | 03/23 | 03/23 | | |
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) |
|
|
| Recruiting | 3 | 16 | US | Paricalcitol | AbbVie | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | 06/26 | 10/26 | | |
| Completed | 2/3 | 36 | Europe | Zemplar | Danderyd Hospital, Abbott | Chronic Kidney Disease | 06/13 | 07/13 | | |
